GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InDex Pharmaceuticals Holding AB (OSTO:INDEX) » Definitions » 3-Year FCF Growth Rate

InDex Pharmaceuticals Holding AB (OSTO:INDEX) 3-Year FCF Growth Rate : 38.30% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is InDex Pharmaceuticals Holding AB 3-Year FCF Growth Rate?

InDex Pharmaceuticals Holding AB's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 38.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of InDex Pharmaceuticals Holding AB was 38.30% per year. The lowest was -99.30% per year. And the median was 9.20% per year.


Competitive Comparison of InDex Pharmaceuticals Holding AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, InDex Pharmaceuticals Holding AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InDex Pharmaceuticals Holding AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InDex Pharmaceuticals Holding AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where InDex Pharmaceuticals Holding AB's 3-Year FCF Growth Rate falls into.



InDex Pharmaceuticals Holding AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


InDex Pharmaceuticals Holding AB  (OSTO:INDEX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


InDex Pharmaceuticals Holding AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of InDex Pharmaceuticals Holding AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


InDex Pharmaceuticals Holding AB (OSTO:INDEX) Business Description

Traded in Other Exchanges
N/A
Address
Berzelius vag 13, Solna, SWE, 171 65
InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Headlines

No Headlines